Antioxidative effect agent for nicotinamide mononucleotide and supplement

Abstract

To use hydrogen to thereby reduce active oxygen produced by the effect of nicotinamide mononucleotide while a body, or a cell of the body can be activated by the effect of the nicotinamide mononucleotide.SOLUTION: An antioxidative effect agent for nicotinamide mononucleotide includes a first material including nicotinamide mononucleotide and a second material including hydrogen. The second material may be a hydrogen storage porous body including a ceramic porous body and hydrogen occluded in the ceramic porous body.SELECTED DRAWING: Figure 3

Description

Technical Field

[0001] The present invention relates to an antioxidant agent and a supplement for nicotinamide mononucleotide (hereinafter referred to as "NMN").

Background Art

[0002] As an antioxidant composition for suppressing aging, for example, Patent Document 1 discloses a composition excellent in anti-aging action by containing NMN and at least one selected from the group consisting of pine bark, banaba, and fulvic acid.

Prior Art Documents

Patent Documents

[0003]

Patent Document 1

Summary of the Invention

Problems to be Solved by the Invention

[0004] Since NMN is a component that contributes to the activation of the body, the body's cells are activated, but at the same time, it also increases reactive oxygen species that become waste products. Therefore, an antioxidant substance that suppresses this is required. However, in the said composition, it is said that anti-aging is achieved by promoting the expression of the SIRTI gene (see

[0064] ). However, the said composition does not mention suppressing the reactive oxygen species generated by the activation of cells.

[0005] In view of the description of Patent Document 1, the present invention aims to solve the above-mentioned problems. That is, the present invention aims to activate the body, that is, activate the body's cells as an action of NMN, and further suppress the reactive oxygen species generated by the action of NMN with hydrogen.

Means for Solving the Problems

[0006] The present invention is as follows. 1. The antioxidant agent for NMN of the present invention is characterized by comprising a first material containing NMN and a second material containing hydrogen. 2. The antioxidant agent for NMN according to 1. above, wherein the second material is a hydrogen storage porous body comprising a ceramic porous body and hydrogen stored in the ceramic porous body. 3. The antioxidant agent for NMN according to 1. above, wherein the ceramic porous body is at least one of a silicon dioxide porous body, a coral porous body, and porous carbon. 4. The antioxidant agent for NMN according to 2. above, wherein when the hydrogen storage porous body is 100% by mass, the hydrogen is 0.01 to 99.99% by mass. 5. The antioxidant agent for NMN according to 1. above, wherein when the total of NMN provided in the first material and hydrogen provided in the second material is 100% by mass, the hydrogen is 0.01 to 99.99% by mass, and the balance is NMN. 6. A supplement characterized by comprising the antioxidant agent for NMN according to any one of 1. to 5. above.

Effects of the Invention

[0007] The present invention can activate the body, that is, activate the cells of the body, by the action of NMN. Further, since active oxygen is generated thereby and may have an adverse effect on health, this active oxygen can be suppressed by the hydrogen of the second material. That is, the present invention can activate the body and suppress active oxygen that is harmful to health, so that the health and anti-aging of the body can be appropriately achieved by the synergistic effect of both.

Brief Description of the Drawings

[0008]

Figure 1

Figure 2

Figure 3

Mode for Carrying Out the Invention

[0009] Hereinafter, the present invention will be described in detail. The antioxidant agent for NMN of the present invention is characterized by comprising a first material containing NMN and a second material containing hydrogen, and the synergistic combination of the two materials is the feature. That is, in the present invention, the first material aims to activate the body, and the second material can suppress the reactive oxygen species generated by the action of NMN. As a result, the two materials are an optimal combination for human health and anti-aging. The present invention is not simply antioxidant of NMN and hydrogen, but in the form of in vivo antioxidant for NMN. The "antioxidant agent for NMN" is used to mean an antioxidant agent that suppresses the reactive oxygen species generated by the action of NMN, and further, an antioxidant agent that aims to activate the body and suppresses the reactive oxygen species generated by the action of NMN.

[0010] (1) First material The first material contains NMN. The NMN is used as a raw material for generating NAD in the body and promotes the activation of the sirtuin gene. Also, the NMN is a nucleotide derived from ribose and nicotinamide and is known as an intermediate metabolite involved in the biosynthesis of NAD+ (nicotinamide adenine dinucleotide). The types of optical isomers of this NMN are not limited. For example, the α-form or β-form can be used, but usually, the β-form is used. Also, the production method of this NMN is not particularly limited, and it can be a fermentation method using yeast, an enzyme synthesis method, a chemical synthesis method, etc. In the present invention, since it is ingested by humans and used orally, the fermentation method using yeast is preferable from the viewpoint of safety.

[0011] The first material may be only NMN, or may include other components depending on the purpose and application, such as nicotinamide riboside (NR) which is a precursor of NMN, or tablet-forming components such as crystalline cellulose, or specific components useful for maintaining and promoting health such as vitamins or minerals, and further other cell-activating components, etc. In this case, when the first material is 100% by mass, the content of NMN can be 0.01 to 100% by mass, preferably 1.0 to 100% by mass, more preferably 10 to 100% by mass. The form of the first material is not particularly limited and can be various forms depending on the purpose and application. For example, the form can be powdery, granular, pellet-like, tablet-like or capsule-like, etc. This capsule-like first material can be obtained by filling the components related to the first material into a capsule container composed of a cylindrical body and a cap. Since the first material is used for human oral use, the material of this capsule container itself is preferably gelatin, a plant-derived material (such as hydroxypropyl methylcellulose), or pullulan made from tapioca starch, etc. Also, the size of the particles in the form of powder or granules, etc. before forming the first material or before filling into the capsule is about 50 to 500 μm, preferably about 50 to 150 μm. Furthermore, in the case of the capsule-like first material, when the other components excluding the capsule container are 100% by mass, the content of NMN can be 0.01 to 100% by mass, preferably 1.0 to 100% by mass, more preferably 10 to 100% by mass.

[0012] The daily intake of NMN for humans can vary depending on the purpose, but it can be 100 - 10,000 mg / day, 200 - 5,000 mg / day, preferably approximately 200 - 1,000 mg / day, and more preferably 400 - 800 mg / day. Also, considering that the NMN content per tablet is about 100 - 300 mg and the daily usage is about 3 tablets, it can be about 300 - 900 mg. The "human" related to the predetermined intake is considered to be an adult aged about 50 - 60 years old and weighing about 40 - 70 kg as tested in the following examples. Furthermore, the required amount of the first material can be used in accordance with the required intake of NMN.

[0013] (2) Second material The second material comprises hydrogen. As shown above, the NMN is a component that contributes to the activation of the body. Instead of activating the body's cells, it also increases reactive oxygen species that become waste products. Therefore, an antioxidant to suppress this is required, and this is hydrogen. It is not simply the antioxidant of NMN and hydrogen, but in the form of in - vivo antioxidant against NMN, that is, this hydrogen is for suppressing and reducing the in - vivo reactive oxygen species generated by the action of NMN in the body. The second material only needs to comprise hydrogen, and other constituent components or substances are not particularly limited. Also, the form of the hydrogen is not particularly limited, and it may be a hydrogen molecule, a hydrogen atom, a hydrogen ion, etc., and is usually considered as a hydrogen molecule. Examples of the second material comprising hydrogen include a hydrogen - storing porous body, an inclusion compound storing hydrogen, and a liquid such as water in which hydrogen is dissolved. This "storage" is used in a broad sense including adsorption.

[0014] The hydrogen - storing porous body can be made to comprise a ceramic - made porous body and hydrogen stored in the ceramic - made porous body. This ceramic - made porous body can be at least one of a porous body made of silicon dioxide, a porous body made of coral, and porous carbon. As the silicon dioxide-based porous body, it has micropores and hydrogen is occluded in these pores, and the size of these pores can be, for example, about 0.1 to 10 nm. Therefore, since this hydrogen-occluding porous body can stably hold hydrogen and has a large hydrogen occlusion amount, it can continuously generate hydrogen for a long time, and its service life can also be extended. Also, the surface can be coated with an aliphatic higher fatty acid such as oleic acid or derived from animals and plants. In this way, hydrogen can be generated after the porous body enters the body and the coating film dissolves further. This can further continuously generate hydrogen for a longer period of time, and its service life can also be made longer. When the hydrogen-occluding porous body is 100% by mass, the hydrogen can be 0.01 to 10% by mass, preferably 0.05 to 5.0% by mass, more preferably 0.1 to 3.0% by mass. And the required amounts of the powdery, granular, particulate and tablet-shaped (excluding capsule containers) contained in the first material can be set according to the required hydrogen intake amount. Furthermore, in the case of the capsule-shaped second material, when the other components excluding the capsule container are 100% by mass, the hydrogen content can be 0.01 to 100% by mass, preferably 1.0 to 100% by mass, more preferably 10 to 100% by mass.

[0015] The form of the second material is not particularly limited as described for the form of the first material, and can be various forms depending on the purpose and use. For example, the form can be powdery, granular, particulate, tablet-shaped or capsule-shaped, etc. Also, the size of the particles such as powdery or particulate before forming the second material or before filling into the capsule is about 50 to 500 μm, preferably about 50 to 150 μm. Furthermore, in the case of the capsule-shaped second material, when the other components excluding the capsule container are 100% by mass, the hydrogen raw material content can be 0.01 to 100% by mass, preferably 1.0 to 100% by mass, more preferably 10 to 100% by mass. And the required amounts of the powdery, granular, particulate, and tablet (excluding capsule containers) forms contained in the second material can be set according to the required hydrogen intake amount.

[0016] (3) Intake amounts of NMN and hydrogen for humans The intake amount of NMN for humans can be 100 - 1500 mg / day, preferably 200 - 1000 mg / day, more preferably 400 - 1000 mg / day. In addition, about 3 capsules can be used per day. Each capsule can be about 100 - 300 mg. In the examples, the intake is 600 mg / day (using 3 capsules of 200 mg each). On the other hand, the intake amount of hydrogen for humans can be 10 - 300 mg / day, preferably 50 - 200 mg / day, more preferably 80 - 120 mg / day. In addition, about 2 capsules can be used per day. Each capsule can be about 40 - 60 mg. In the examples, the intake is 100 mg / day (using 2 capsules of 50 mg each). The intake amounts can be appropriately combined with each of the above-mentioned NMN intake amounts and each of the above-mentioned hydrogen intake amounts. Thereby, the required amounts (intake amounts) of the necessary first material and second material can be set.

[0017] (4) Supplements This supplement is characterized by consisting of an antioxidant agent for the above-mentioned NMN. Generally, supplements are considered to be useful for maintaining and promoting health. Since the supplement of the present invention includes not only the hydrogen of the second material but also the NMN of the first material, it functions as a supplement. Also, specific components useful for maintaining and promoting health, such as vitamins and minerals usually formulated in supplements, can also be formulated in this supplement. Furthermore, it can also be formulated with resveratrol, nicotinamide riboside (NR) which is a precursor of NMN, vitamin B1, vitamin B2, vitamin B6, and nicotinamide, which are often used as support components. Also, regarding the capsules used in this supplement, the above description can be applied as it is. That is, the shape or form of this supplement can usually be granular, tableted, obtained by compressing or molding raw material materials such as predetermined powders, or a capsule-shaped body in which a cylindrical body and a cap are filled with a predetermined material. Since the capsule is used orally, it is preferable to use gelatin, a plant-derived material (such as hydroxypropylmethylcellulose), or pullulan made from tapioca starch as a raw material. Furthermore, each of the first material and the second material can be made into separate tablets or capsule-shaped bodies. Also, in order to prevent the two materials from coming into direct contact, a partition can be provided in one capsule to separately store each powder or tablet, etc., or one of them can be made into a small capsule body and stored in a large capsule. The intake amount of the supplement can also be the same as that shown in the column of "Intake Amount of NMN and Hydrogen for Humans".

Examples

[0018] Hereinafter, the present invention will be described in more detail with reference to examples. However, the present invention is not limited to these examples, and the present invention can take various forms as long as the problems of the present invention can be solved.

[0019] (1) Test method; As a test, in the NMN intake group and the NMN + hydrogen intake group, a test was conducted using an antioxidant marker of 8-OHdG (8-hydroxydeoxyguanosine) using urine to see how antioxidant levels changed. This test can measure the antioxidant status in the body of 8-OHdG. That is, when the human body has an oxidative tendency, a part of the nucleic acid is oxidized and 8-OHdG comes out with urine. This test measures this 8-OHdG. Specifically, it was carried out as follows. The types and compositions of the raw materials used are as follows. The first material used is a first supplement containing NMN, and the second material is a second supplement made of a hydrogen-storing ceramic porous body (a porous body made of silica dioxide in which hydrogen is stored). The compounding components of the first material and their compounding ratios, etc. are as follows. NMN (30 - 75% by mass) Crystalline cellulose (20 - 40% by mass) Microcrystalline silicon dioxide (1 - 2% by mass) Calcium stearate (0.5 - 2% by mass) Oleic acid (1 - 5% by mass) Hydrogen raw material (0.5 - 25% by mass) Also, Table 1 shows three subjects (A, B, and C), the specimen collection dates (September 4th, September 7th, and September 14th), urine volume, urine retention time, etc. "F" indicates female.

[0020]

Table 1

[0021] Furthermore, the test setup is as follows. Each subject was asked to conduct their normal daily life and dietary intake, and the experiment was carried out in such a way that they did not consume anything other than the supplements they took. (a) Day 0; Morning urine sample was collected. After that, the intake of the first NMN supplement was started. In this case, the NMN intake was 600 mg / day (200 mg / capsule × 3 capsules / day). (b) Day 3; Morning urine sample was collected. After that, the intake of the first (NMN) and second supplements (hydrogen) was started. In this case, the hydrogen raw material intake was 100 mg / day (50 mg / capsule × 2 capsules / day). (c) Day 10; Morning urine sample was collected. The intake of the first and second supplements was carried out by putting them in separate capsules for ingestion. No specific guideline was set for the intake time for each day. This time, 3 capsules of the first capsule and 2 capsules of the second capsule were ingested within a day.

[0022] (2) Test results: Analysis of urinary 8-OHdG was performed, and the results are shown in Table 2. "F" indicates female.

[0023]

Table 2

[0024] For urine specimens, those collected in the morning were frozen with dry ice and sent to the analysis institution together with dry ice for analysis. The results of this analysis are shown in Table 1 and Figures 1 to 3. These show the results of three types: without the use of NMN and hydrogen, with the use of only NMN, and with the use of both. In particular, Figures 1 to 3 show the comparison results for the above three types for each subject. Figure 1 shows 8-OHdG in urine, Figure 2 shows the production rate of 8-OHdG in urine, and Figure 3 shows the results of creatinine correction of 8-OHdG in urine. In addition, the creatinine correction value was calculated by the following formula. Creatinine correction value (mg / g·Cre) = measured value (mg / dl) × 1000 / Cre concentration (mg / dl) The significance of this creatinine correction is as follows. That is, creatinine is the final metabolite of creatine and is utilized for urine volume error due to the property that the excretion amount is constant. There are diurnal variations in the excretion of urinary components and urine volume, and there is a possibility of false positives and false negatives when using random urine. Therefore, by using creatinine correction, it is possible to evaluate with only the urine collection at that time without collecting 24-hour urine.

[0025] Compared with the case without including this (comparative example), except for the case of creatinine correction of Subject A in Figure 3, all others show a decrease in the 8-OHdG concentration in urine, the production rate of 8-OHdG in urine, and the creatinine correction of 8-OHdG in urine, indicating the NMN effect. However, even if there is an effect of using NMN, as shown by the results when hydrogen is used in combination, it can be seen that it has not decreased to this extent. Moreover, when both are ingested (Example of the present invention), compared with the case of only NMN (Comparative Example), except for the case of creatinine correction of Mr. C in Fig. 3, in all other cases, the urinary 8-OHdG concentration, the urinary 8-OHdG production rate, and the urinary 8-OHdG creatinine correction have decreased, indicating an excellent effect when both NMN and hydrogen are used in the Example of the present invention compared to the case of NMN alone.

[0026] Also, when both are ingested (Example of the present invention), compared with the case where neither is used (Comparative Example), the urinary 8-OHdG concentration (Fig. 1), the urinary 8-OHdG production rate (Fig. 2), and the urinary 8-OHdG creatinine correction (Fig. 3) have all decreased significantly, and the ratios of those values are 1 / 29, 1 / 1.8, 1 / 3.0 (Fig. 1), 1 / 13, 1 / 4.8, 1 / 2.4 (Fig. 2), 1 / 2.5, 1 / 2.2, 1 / 1.3 (Fig. 3) respectively, showing a very excellent effect in all cases of the Example of the present invention. Furthermore, when both are ingested (Example of the present invention), compared with the case of using only NMN (Comparative Example), in the urinary 8-OHdG concentration (Fig. 1), the urinary 8-OHdG production rate (Fig. 2), and the urinary 8-OHdG creatinine correction (Fig. 3), only the case of Mr. C shows almost no change, but in other cases, all have decreased significantly, and the ratios of those values are 1 / 19, 1 / 1.4, 1 / 1.1 (Fig. 1), 1 / 6.9, 1 / 3.2, 1 / 1.0 (Fig. 2), 1 / 2.9, 1 / 1.7, 1 / 1.0 (Fig. 3) respectively, showing a very excellent effect in all cases of the Example of the present invention. From the above points, the examples of the present invention show a great synergistic effect by the combination of the two materials.

Industrial Applicability

[0027] The present invention has the effect of making people healthy and further preventing aging, and is widely used in health foods, supplements, drugs, etc., and is utilized for the activation of industries related thereto.

Claims

1. An antioxidant for nicotinamide mononucleotide, comprising a first material containing nicotinamide mononucleotide and a second material containing hydrogen.

2. The antioxidant for nicotinamide mononucleotide according to claim 1, wherein the second material is a hydrogen storage porous body comprising a ceramic porous body and hydrogen stored in the ceramic porous body.

3. The antioxidant for nicotinamide mononucleotide according to claim 1, wherein the ceramic porous body is at least one of a porous body made of silicon dioxide, a porous body made of coral, and porous carbon.

4. The antioxidant for nicotinamide mononucleotide according to claim 1, wherein when the hydrogen storage porous body is 100% by mass, the hydrogen is 0.01 to 99.99% by mass.

5. The antioxidant for nicotinamide mononucleotide according to claim 1, wherein when the total of the nicotinamide mononucleotide provided in the first material and the hydrogen provided in the second material is 100% by mass, the hydrogen is 0.01 to 99.99% by mass, and the balance is the nicotinamide mononucleotide.

6. A supplement comprising the antioxidant for nicotinamide mononucleotide according to any one of claims 1 to 5.

Images